{
    "nct_id": "NCT04856189",
    "official_title": "A Phase Ib/II Study of Selinexor Plus Pembrolizumab in Cisplatin-Ineligible or Cisplatin-Refractory Patients With Advanced Urothelial Carcinoma",
    "inclusion_criteria": "* Pathologically confirmed locally advanced or metastatic urothelial carcinoma by histology\n* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1\n* Not eligible to receive cisplatin-based chemotherapy due to renal dysfunction (defined as creatinine clearance [CrCl] =< 60 mL/min), > grade 2 peripheral neuropathy, or ototoxicity (defined as >= grade 2 hearing loss); OR unwillingness of patient to receive cisplatin; OR progressed on one platinum-based chemotherapy regimen for advanced disease\n* May have had neoadjuvant or adjuvant platinum-based chemotherapy or intravesical therapy in the past\n* >= 18 years of age\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2\n* Life expectancy >= 3 months\n* Absolute neutrophil count (ANC) >= 1 × 10^9/L\n* Platelet count >= 75 × 10^9/L (patients for whom <50% of bone marrow nucleated cells are plasma cells) or >= 50,000/mm3 (patients for whom >= 50% of bone marrow nucleated cells are plasma cells)\n* Hemoglobin >= 9 g/dL (may have been transfused)\n* Total bilirubin level =< 1.5 x the upper limit of normal (ULN) range (except patients with Gilbert's syndrome who must have a total bilirubin of < 3 x ULN)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN, or AST and ALT levels =< 5 x ULN (for subjects with documented metastatic disease to the liver)\n* Creatinine clearance >= 30 mL/min by Cockcroft-Gault formula\n* Subjects with active hepatitis B virus (Hep B) are allowed if antiviral therapy for hepatitis B has been given for > 8 weeks and viral load is < 100 IU/mL prior to first dose of trial treatment. Subjects with untreated hepatitis C virus (HCV) are allowed. Subjects with human immunodeficiency virus (HIV) who have CD4+ T-cell counts >= 350 cells/uL and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections in the last year are allowed\n* Willingness to undergo mandatory pre-treatment biopsy (unless there is adequate archival tumor specimen available for PD-L1 IHC evaluation)\n* Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for >= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Or, female subjects of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the first study drug administration\n* Male and female subjects who are of reproductive potential must agree to use highly effective method of birth control (e.g., implants, injectables, birth control pills with two hormones, intrauterine devices [IUDs], complete abstinence or sterilized partner, and female sterilization) and a barrier method (e.g., condoms, vaginal ring, sponge, etc.) during the period of therapy and for 4 months after the last dose of study drug\n* Ability to understand and willingness to sign an informed consent form\n* Ability to adhere to the study visit schedule and other protocol requirements\n* Must be able to swallow study drug\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Receiving radiation =< 14 days prior to enrollment to the site of selected target lesions\n* Systemic therapy for cancer =< 21 days prior to enrollment\n* Autoimmune disorder requiring active therapy as defined by corticosteroids at a dose >= 10 mg oral prednisone or the equivalent or requiring chronic immunosuppressive therapy\n* Use of corticosteroids =< 14 days prior to enrollment at a dose of >= 10 mg oral prednisone or the equivalent per day\n* Received immune checkpoint inhibitor therapy (anti-PD-1, anti-PD-L1, or anti-CTLA4 directed therapy) on a prior clinical trial\n* Has received selinexor or another XPO1 inhibitor previously\n* Any active gastrointestinal dysfunction that could interfere with absorption of study treatment in the opinion of the investigator\n* Pregnant or lactating women\n* Any condition that would prohibit the understanding or rendering of informed consent\n* Any condition including additional malignancies, laboratory abnormalities, or psychiatric illness that in the opinion of the investigator would interfere with the patient's safety or compliance while on trial\n* Severe infection that in the opinion of the investigator would interfere with patient safety or compliance on trial within 4 weeks prior to enrollment",
    "miscellaneous_criteria": ""
}